RxDoctor Payments Data

Steven Clarkson

Family · Greenwood, INNPI 1659871903

Payments from drug & device makers

$2,242in general payments, 2019–2025

Across 146 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$384
  • AbbVie$352
  • Pfizer$213
  • Lilly USA, LLC$192
  • AstraZeneca$158
  • Exact Sciences$111
  • plus $833 from 17 others

What the payments were for

  • Food & beverage$2,234100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,242 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$35,170
Medicare patients
189
Services billed
416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$51,205
RybelsusSemaglutide16$25,648
FarxigaDapagliflozin Propanediol19$16,056
EliquisApixaban20$14,485
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,382
Breo ElliptaFluticasone/Vilanterol17$9,752
JardianceEmpagliflozin14$9,692
JanuviaSitagliptin Phosphate11$6,174
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,182
Vilazodone Hcl18$2,032
SynthroidLevothyroxine Sodium18$1,152
Buspirone Hcl43$907
Gabapentin59$847
Ezetimibe23$793
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf11$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$384$76,85472 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$65$26,31652 claims
AstraZenecaFarxiga$158$16,05619 claims
PfizerEliquis$213$14,48520 claims
Boehringer IngelheimJardiance$71$9,69214 claims
MerckJanuvia$107$6,17411 claims
AbbVieSynthroid$352$1,15218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →